6 O
ADVERSE O
REACTIONS O
LABA O
, O
such O
as O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANORO O
ELLIPTA O
, O
increase O
the O
risk O
of O
asthma B-OSE_Labeled_AE
-related O
death B-NonOSE_AE
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
. O

[ O
See O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
. O
] O

The O
following O
adverse O
reactions O
are O
described O
in O
greater O
detail O
in O
other O
sections O
: O
* O
Paradoxical B-OSE_Labeled_AE
bronchospasm I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Cardiovascular B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Worsening O
of O
narrow B-OSE_Labeled_AE
- I-OSE_Labeled_AE
angle I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Worsening O
of O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=1 O
% O
and O
more O
common O
than O
placebo O
) O
include O
pharyngitis O
, O
sinusitis O
, O
lower O
respiratory O
tract O
infection O
, O
constipation O
, O
diarrhea O
, O
pain O
in O
extremity O
, O
muscle O
spasms O
, O
neck O
pain O
, O
and O
chest O
pain O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
http O
: O
//www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
clinical O
program O
for O
ANORO O
ELLIPTA O
included O
8,138 O
subjects O
with O
COPD B-Not_AE_Candidate
in O
four O
6-month O
lung O
function O
trials O
, O
one O
12-month O
long-term O
safety O
study O
, O
and O
9 O
other O
trials O
of O
shorter O
duration O
. O

A O
total O
of O
1,124 O
subjects O
have O
received O
at O
least O
1 O
dose O
of O
ANORO O
ELLIPTA O
( O
umeclidinium/vilanterol O
62.5 O
mcg/25 O
mcg O
) O
, O
and O
1,330 O
subjects O
have O
received O
a O
higher O
dose O
of O
umeclidinium/vilanterol O
( O
125 O
mcg/25 O
mcg O
) O
. O

The O
safety O
data O
described O
below O
are O
based O
on O
the O
four O
6-month O
and O
the O
one O
12-month O
trials O
. O

Adverse O
reactions O
observed O
in O
the O
other O
trials O
were O
similar O
to O
those O
observed O
in O
the O
confirmatory O
trials O
. O

6-Month O
Trials O
: O
The O
incidence O
of O
adverse O
reactions O
associated O
with O
ANORO O
ELLIPTA O
in O
Table O
1 O
is O
based O
on O
four O
6-month O
trials O
: O
2 O
placebo-controlled O
trials O
( O
Trials O
1 O
and O
2 O
; O
n O
= O
1,532 O
and O
n O
= O
1,489 O
, O
respectively O
) O
and O
2 O
active-controlled O
trials O
( O
Trials O
3 O
and O
4 O
; O
n O
= O
843 O
and O
n O
= O
869 O
, O
respectively O
) O
. O

Of O
the O
4,733 O
subjects O
, O
68 O
% O
were O
male O
and O
84 O
% O
were O
Caucasian O
. O

They O
had O
a O
mean O
age O
of O
63 O
years O
and O
an O
average O
smoking O
history O
of O
45 O
pack-years O
, O
with O
50 O
% O
identified O
as O
current O
smokers O
. O

At O
screening O
, O
the O
mean O
post-bronchodilator O
percent O
predicted O
forced O
expiratory O
volume O
in O
1 O
second O
( O
FEV1 O
) O
was O
48 O
% O
( O
range O
: O
13 O
% O
to O
76 O
% O
) O
, O
the O
mean O
post-bronchodilator O
FEV1/forced O
vital O
capacity O
( O
FVC O
) O
ratio O
was O
0.47 O
( O
range O
: O
0.13 O
to O
0.78 O
) O
, O
and O
the O
mean O
percent O
reversibility O
was O
14 O
% O
( O
range O
: O
-45 O
% O
to O
109 O
% O
) O
. O

Subjects O
received O
1 O
dose O
once O
daily O
of O
the O
following O
: O
ANORO O
ELLIPTA O
, O
umeclidinium/vilanterol O
125 O
mcg/25 O
mcg O
, O
umeclidinium O
62.5 O
mcg O
, O
umeclidinium O
125 O
mcg O
, O
vilanterol O
25 O
mcg O
, O
active O
control O
, O
or O
placebo O
. O

Table O
1 O
. O

Adverse O
Reactions O
With O
ANORO O
ELLIPTA O
With O
> O
=1 O
% O
Incidence O
and O
More O
Common O
Than O
With O
Placebo O
in O
Subjects O
With O
Chronic O
Obstructive O
Pulmonary O
Disease O
Adverse O
Reaction O
Placebo O
( O
n O
= O
555 O
) O
% O
ANORO O
ELLIPTA O
( O
n O
= O
842 O
) O
% O
Umeclidinium O
62.5 O
mcg O
( O
n O
= O
418 O
) O
% O
Vilanterol O
25 O
mcg O
( O
n O
= O
1,034 O
) O
% O
Infections B-NonOSE_AE
and O
infestations O
Pharyngitis B-OSE_Labeled_AE
< O
1 O
2 O
1 O
2 O
Sinusitis B-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
1 O
Lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Constipation B-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Diarrhea B-OSE_Labeled_AE
1 O
2 O
< O
1 O
2 O
Musculoskeletal B-NonOSE_AE
and O
connective O
tissue O
disorder I-NonOSE_AE
s O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
1 O
2 O
< O
1 O
2 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and O
administration O
site O
conditions O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Other O
adverse O
reactions O
with O
ANORO O
ELLIPTA O
observed O
with O
an O
incidence O
less O
than O
1 O
% O
but O
more O
common O
than O
with O
placebo O
included O
the O
following O
: O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
and O
conjunctivitis B-OSE_Labeled_AE
. O

12-Month O
Trial O
: O
In O
a O
long-term O
safety O
trial O
, O
335 O
subjects O
were O
treated O
for O
up O
to O
12 O
months O
with O
umeclidinium/vilanterol O
125 O
mcg/25 O
mcg O
or O
placebo O
. O

The O
demographic O
and O
baseline O
characteristics O
of O
the O
long-term O
safety O
trial O
were O
similar O
to O
those O
of O
the O
placebo-controlled O
efficacy O
trials O
described O
above O
. O

Adverse O
reactions O
that O
occurred O
with O
a O
frequency O
of O
greater O
than O
or O
equal O
to O
1 O
% O
in O
the O
group O
receiving O
umeclidinium/vilanterol O
125 O
mcg/25 O
mcg O
that O
exceeded O
that O
in O
placebo O
in O
this O
trial O
were O
: O
headache B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pleuritic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
, O
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
. O

